AR029451A1 - Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia - Google Patents

Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Info

Publication number
AR029451A1
AR029451A1 ARP000102365A ARP000102365A AR029451A1 AR 029451 A1 AR029451 A1 AR 029451A1 AR P000102365 A ARP000102365 A AR P000102365A AR P000102365 A ARP000102365 A AR P000102365A AR 029451 A1 AR029451 A1 AR 029451A1
Authority
AR
Argentina
Prior art keywords
therapy
breast cancer
product
composition
human beings
Prior art date
Application number
ARP000102365A
Other languages
English (en)
Inventor
Salle Enrico Di
Tiziana Zaccheo
Michele Tedeschi
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of AR029451A1 publication Critical patent/AR029451A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un producto para su uso en la terapia para el cáncer de mamas en seres humanos, que contiene un agente antineoplásico y un inhibidor de aromatasa, en cantidades efectivas para producir un efecto antitumoral superaditivo, para su administracion en forma separada, simultánea o secuencial en la terapia para el cáncer de mamas en seres humanos.
ARP000102365A 1999-05-18 2000-05-17 Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia AR029451A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9911582.6A GB9911582D0 (en) 1999-05-18 1999-05-18 Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound

Publications (1)

Publication Number Publication Date
AR029451A1 true AR029451A1 (es) 2003-07-02

Family

ID=10853700

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102365A AR029451A1 (es) 1999-05-18 2000-05-17 Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia

Country Status (6)

Country Link
EP (1) EP1178831A1 (es)
JP (1) JP2003512301A (es)
AR (1) AR029451A1 (es)
AU (1) AU3820700A (es)
GB (1) GB9911582D0 (es)
WO (1) WO2000069467A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030043955A (ko) * 2000-09-08 2003-06-02 파마시아 이탈리아 에스.피.에이. 화학적 예방제로서 엑스메스탄
EA200300572A1 (ru) * 2000-11-16 2004-06-24 Фармация Энд Апджон Компани Комбинированная терапия эстроген-зависимых заболеваний
EP2762140B1 (en) 2001-02-19 2017-03-22 Novartis AG Treatment of solid brain tumours with a rapamycin derivative
CZ299756B6 (cs) * 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
ES2694582T3 (es) 2011-01-31 2018-12-21 Lucolas-M.D. Ltd. Combinaciones de inhibidores de aromatasa y antioxidantes
CN107405353B (zh) 2014-10-22 2021-07-30 哈瓦赫治疗有限公司 降低乳房摄影乳腺密度和/或乳腺癌风险的方法
WO2017066827A1 (en) 2015-10-22 2017-04-27 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Also Published As

Publication number Publication date
AU3820700A (en) 2000-12-05
GB9911582D0 (en) 1999-07-21
JP2003512301A (ja) 2003-04-02
WO2000069467A1 (en) 2000-11-23
EP1178831A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
AR033555A1 (es) Producto para el tratamiento del carcinoma de receptor de estrogeno positivo, y uso de dicho producto para preparar medicamentos
AR028296A1 (es) Metodos sinergisticos y composiciones para el tratamiento del cancer
CO4290346A1 (es) Formas de dosificacion de liberacion controlada de azitromicina
ES2148838T3 (es) Oligonucleotidos antisentido contra la subunidad reguladora alfa de la proteina quinasa dependiente de camp para el tratamiento del cancer.
TR200000576T1 (tr) Lipozomal kapsüllenmiş taksan uygulanması için bir yöntem
AR019855A1 (es) Uso de conjugados de peg-ifn-alfa y ribavirina para la fabricacion de un medicamento para el tratamiento de hepatitis c cronica
PA8479201A1 (es) Derivados del acido hidroxi-pipecolato hidroxamico
AR045179A1 (es) Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
AR082579A2 (es) Una composicion farmaceutica espontaneamente dispersable para la administracion oral, uso para la preparacion de un medicamento para el tratamiento del cancer, metodo para incrementar los niveles de biodisponibilidad o reducir su variabilidad
AR027355A1 (es) Acidos tiazolidincarboxilicos
DK1259240T3 (da) Midler, såsom nikotinamid eller CADPR, til behandling af hudsygdomme
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
HRPK20041072B3 (en) Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer
MY138883A (en) Use of asiatic acid for treatment of cencer
AR029451A1 (es) Una composicion para su uso en la terapia del cancer de mamas en seres humanos y un producto para su uso en dicha terapia
AR024564A1 (es) Composicion que comprende esfingomielinasa para el uso como una preparacion dietetica, suplemento dietario o producto farmaceutico
HUP0400153A2 (en) Product comprising mikanolide, dihydromikanolide or an analogue thereof combined with another anti-cancer agent for therapeutic use in cancer treatment
ES2172171T3 (es) Medicamento, que contiene yohimbina y arginina, para el tratamiento de disfunciones erectiles.
MXPA02010184A (es) Formulaciones topicas para el suministro transdermico de niacina y metodos para tratar hiperlipidemia.
ATE399558T1 (de) Anti-tumorale formulierungen mit defibrotid allein oder in kombination mit anderen antitumoralen mitteln
HUP0203153A2 (hu) Kombinációs kemoterápia
ATE294585T1 (de) Vorbeugung von kolorektalkrebs
CY1107227T1 (el) Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ
AR024981A1 (es) Composicion para la prevencion y el tratamiento de las disfunciones y enfermedades del rinon
TR200002847T2 (tr) Biçim VI 5, 6-dikloro-2-(izopropilamino) -1-(beta-L-ribofüranosil) -1H-benzimidazol.

Legal Events

Date Code Title Description
FB Suspension of granting procedure